{"id":"brimonidine-tartrate-ophthalmic-solution","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Ocular hyperemia (eye redness)"},{"rate":"10-15","effect":"Ocular allergic reactions"},{"rate":"10-15","effect":"Dry mouth"},{"rate":"5-10","effect":"Fatigue"},{"rate":"5-10","effect":"Headache"},{"rate":"5","effect":"Blurred vision"},{"rate":null,"effect":"Tachyphylaxis (reduced efficacy over time)"}]},"_chembl":null,"_dailymed":{"setId":"e1ea003e-3dd9-41c7-9119-d1f209b9820b","title":"BRIMONIDINE TARTRATE OPHTHALMIC SOLUTION, 0.15% SOLUTION/ DROPS [ALEMBIC PHARMACEUTICALS LIMITED]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Brimonidine selectively binds to alpha-2 adrenergic receptors on the ciliary body and trabecular meshwork of the eye. This activation reduces the production of aqueous humor (the fluid inside the eye) and enhances its drainage through the uveoscleral pathway, thereby lowering intraocular pressure. The drug has minimal systemic absorption when applied topically to the eye.","oneSentence":"Brimonidine tartrate is an alpha-2 adrenergic receptor agonist that reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:45:00.006Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT04774237","phase":"PHASE2","title":"Safety and Efficacy Study of BRIMOCHOL™, BRIMOCHOL™ F, and Carbachol in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia","status":"COMPLETED","sponsor":"Visus Therapeutics","startDate":"2021-03-24","conditions":"Presbyopia","enrollment":18},{"nctId":"NCT06365853","phase":"PHASE2","title":"A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-07-29","conditions":"Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive","enrollment":100},{"nctId":"NCT05728944","phase":"PHASE3","title":"Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia","status":"COMPLETED","sponsor":"LENZ Therapeutics, Inc","startDate":"2023-03-06","conditions":"Presbyopia, Near Vision, Refractive Error","enrollment":229},{"nctId":"NCT05656027","phase":"PHASE3","title":"Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia","status":"COMPLETED","sponsor":"LENZ Therapeutics, Inc","startDate":"2022-12-19","conditions":"Presbyopia, Refractive Error, Eye Diseases","enrollment":469},{"nctId":"NCT07390578","phase":"PHASE4","title":"Upneeq vs. Lumify Ptosis","status":"NOT_YET_RECRUITING","sponsor":"Duke University","startDate":"2026-03-01","conditions":"Acquired Ptosis","enrollment":50},{"nctId":"NCT07209410","phase":"PHASE4","title":"Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma","status":"RECRUITING","sponsor":"Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,","startDate":"2025-11-01","conditions":"Glaucoma","enrollment":35},{"nctId":"NCT04007276","phase":"PHASE4","title":"The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients","status":"NOT_YET_RECRUITING","sponsor":"Tulane University","startDate":"2026-11-10","conditions":"Glaucoma, Glaucoma, Open-Angle, Glaucoma; Drugs","enrollment":60},{"nctId":"NCT05135286","phase":"PHASE3","title":"Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia","status":"COMPLETED","sponsor":"Visus Therapeutics","startDate":"2022-03-15","conditions":"Presbyopia","enrollment":629},{"nctId":"NCT05815758","phase":"PHASE3","title":"Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2023-04-20","conditions":"Allergic Conjunctivitis","enrollment":512},{"nctId":"NCT06803654","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular Redness","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2025-05-22","conditions":"Ocular Redness","enrollment":578},{"nctId":"NCT05591755","phase":"PHASE3","title":"Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2022-11-18","conditions":"Seasonal Allergic Conjunctivitis","enrollment":229},{"nctId":"NCT06996236","phase":"PHASE2","title":"Brimonidine Eye Drops in the Prevention of Myopia Progression","status":"NOT_YET_RECRUITING","sponsor":"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","startDate":"2025-07","conditions":"Myopia","enrollment":40},{"nctId":"NCT06883123","phase":"PHASE4","title":"Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost","status":"RECRUITING","sponsor":"Prairie Eye Center","startDate":"2025-05-14","conditions":"Open Angle Glaucoma","enrollment":70},{"nctId":"NCT06948357","phase":"PHASE2","title":"Efficacy and Safety of BRIMOCHOL PF and CARBACHOL PF in Chinese Presbyopia Patients","status":"RECRUITING","sponsor":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","startDate":"2025-03-24","conditions":"Presbyopia","enrollment":119},{"nctId":"NCT06078592","phase":"PHASE4","title":"Comparison of Efficacy and Ocular Surface Assessment Between BRIDIN-plus and Combigan in Glaucoma or Ocular Hypertensive","status":"COMPLETED","sponsor":"CHA University","startDate":"2021-10-08","conditions":"Glaucoma, Ocular Hypertensive","enrollment":60},{"nctId":"NCT03193333","phase":"PHASE3","title":"PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)","status":"TERMINATED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2017-11-06","conditions":"Primary Open-angle Glaucoma","enrollment":51},{"nctId":"NCT06045299","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia","status":"COMPLETED","sponsor":"Corxel Pharmaceuticals","startDate":"2023-09-27","conditions":"Presbyopia, Near Vision, Miosis","enrollment":300},{"nctId":"NCT05579730","phase":"PHASE3","title":"Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2022-10-12","conditions":"Allergic Conjunctivitis","enrollment":188},{"nctId":"NCT06761313","phase":"PHASE4","title":"Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Federal University of São Paulo","startDate":"2021-03-01","conditions":"Glaucoma, Quality of Life (QOL)","enrollment":40},{"nctId":"NCT05753189","phase":"PHASE3","title":"Phase 3 Safety Study for the Treatment of Presbyopia Subjects","status":"COMPLETED","sponsor":"LENZ Therapeutics, Inc","startDate":"2023-02-21","conditions":"Presbyopia, Near Vision, Miosis","enrollment":362},{"nctId":"NCT05270863","phase":"PHASE3","title":"Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia","status":"COMPLETED","sponsor":"Visus Therapeutics","startDate":"2022-03-30","conditions":"Presbyopia","enrollment":182},{"nctId":"NCT05431543","phase":"PHASE2","title":"Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia","status":"COMPLETED","sponsor":"LENZ Therapeutics, Inc","startDate":"2022-08-06","conditions":"Presbyopia, Refractive Errors, Eye Diseases","enrollment":59},{"nctId":"NCT05294328","phase":"PHASE2","title":"Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia","status":"COMPLETED","sponsor":"LENZ Therapeutics, Inc","startDate":"2022-05-05","conditions":"Presbyopia, Refractive Errors, Eye Diseases","enrollment":68},{"nctId":"NCT05360784","phase":"PHASE3","title":"\"Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness\"","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2022-05-13","conditions":"Ocular Redness","enrollment":380},{"nctId":"NCT06270030","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Chinese With Presbyopia","status":"COMPLETED","sponsor":"Corxel Pharmaceuticals","startDate":"2024-03-04","conditions":"Presbyopia","enrollment":21},{"nctId":"NCT03235232","phase":"PHASE3","title":"BREMEN Eye Drops Versus Combigan for Open-angle Glaucoma or Intraocular Hypertension","status":"COMPLETED","sponsor":"EMS","startDate":"2021-02-01","conditions":"Ocular Hypertension, Primary Open-angle Glaucoma","enrollment":406},{"nctId":"NCT06177678","phase":"PHASE2","title":"A Randomized, Open-label, Active-controlled, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-angle Glaucoma or Ocular Hypertension","status":"UNKNOWN","sponsor":"Kukje Pharma","startDate":"2024-02","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":60},{"nctId":"NCT04702789","phase":"PHASE4","title":"Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.","status":"TERMINATED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2021-10-19","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":28},{"nctId":"NCT01144494","phase":"EARLY_PHASE1","title":"Aqueous Humor Dynamics and Brimonidine","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2010-08-01","conditions":"Intraocular Pressure","enrollment":35},{"nctId":"NCT05936489","phase":"PHASE1","title":"Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia","status":"COMPLETED","sponsor":"LENZ Therapeutics, Inc","startDate":"2023-07-06","conditions":"Eye Diseases, Presbyopia, Refractive Errors","enrollment":30},{"nctId":"NCT05940623","phase":"NA","title":"Impact of Home Intraocular Pressure Telemonitoring on Intraocular Pressure Control and Glaucoma Progression","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2023-08-24","conditions":"Glaucoma, Intraocular Pressure, Primary Open Angle Glaucoma","enrollment":142},{"nctId":"NCT02623023","phase":"NA","title":"Prophylaxis for Anti-VEGF-induced IOP Elevation","status":"WITHDRAWN","sponsor":"McMaster University","startDate":"2019-01-01","conditions":"Ocular Hypertension","enrollment":""},{"nctId":"NCT04741919","phase":"NA","title":"Superior vs Temporal Laser Peripheral Iridotomy in Primary Angle Closure Suspects (PACS)","status":"UNKNOWN","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2020-11-25","conditions":"Primary Angle Glaucoma Closure Suspect","enrollment":200},{"nctId":"NCT05474716","phase":"PHASE4","title":"The Effect of Topical Brimonidine on the Ocular Hemodynamics in Patients of POAG Using OCTA","status":"COMPLETED","sponsor":"Fayoum University","startDate":"2020-05-01","conditions":"Glaucoma, Primary Open Angle, Ocular Blood Flow, Optical Coherence Tomography Angiography","enrollment":41},{"nctId":"NCT05231928","phase":"NA","title":"A Novel Argon Laser Iridoplasty for Pigment Dispersion Syndrome","status":"UNKNOWN","sponsor":"Fayoum University","startDate":"2021-12-01","conditions":"Pigment Dispersion Syndrome, Pigmentary Glaucoma","enrollment":10},{"nctId":"NCT03785340","phase":"PHASE3","title":"Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)","status":"COMPLETED","sponsor":"Ocugen","startDate":"2018-12-03","conditions":"Dry Eye","enrollment":252},{"nctId":"NCT03591874","phase":"PHASE3","title":"Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease","status":"TERMINATED","sponsor":"Ocugen","startDate":"2018-12-23","conditions":"Graft Versus Host Disease, Ocular Surface Disease, oGVHD","enrollment":59},{"nctId":"NCT03418727","phase":"PHASE2","title":"Dry Eye Disease Study With Brimonidine","status":"COMPLETED","sponsor":"Ocugen","startDate":"2017-09-06","conditions":"Dry Eye","enrollment":84},{"nctId":"NCT03760185","phase":"PHASE2","title":"Pupil Dilation for Treatment of IFIS","status":"COMPLETED","sponsor":"Denver Health and Hospital Authority","startDate":"2019-01-04","conditions":"Intraoperative Floppy Iris Syndrome","enrollment":13},{"nctId":"NCT05241938","phase":"NA","title":"PSLT Compared to Prostaglandin Analogue Eye Drops","status":"UNKNOWN","sponsor":"Federal University of Rio Grande do Sul","startDate":"2021-09-01","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":75},{"nctId":"NCT03450629","phase":"PHASE3","title":"Evaluation of Safety and Efficacy of PDP-716","status":"COMPLETED","sponsor":"Sun Pharma Advanced Research Company Limited","startDate":"2018-09-13","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":682},{"nctId":"NCT03220490","phase":"NA","title":"Efficacy and Necessity of Time Interval Between Instillation of Two Glaucoma Eye Drops","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2017-11-01","conditions":"Glaucoma, Glaucoma; Drugs","enrollment":65},{"nctId":"NCT05006898","phase":"PHASE1","title":"Compound to Control Presbyopia Symptoms","status":"COMPLETED","sponsor":"Optall Vision","startDate":"2020-06-01","conditions":"Presbyopia","enrollment":11},{"nctId":"NCT05001243","phase":"PHASE1","title":"Comparison of a Compound With Pilocarpine and Brimonidine to Improve Near Vision in Healthy Presbyopic Patients","status":"UNKNOWN","sponsor":"Optall Vision","startDate":"2021-08-10","conditions":"Presbyopia","enrollment":11},{"nctId":"NCT03782701","phase":"PHASE4","title":"The Effect of Lumify™ Eyedrops on Eyelid Position","status":"COMPLETED","sponsor":"University of Miami","startDate":"2019-06-18","conditions":"Eyelid Droop","enrollment":43},{"nctId":"NCT00697541","phase":"PHASE2","title":"Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2008-05","conditions":"Erythematous Rosacea","enrollment":20},{"nctId":"NCT03323164","phase":"PHASE4","title":"Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study","status":"COMPLETED","sponsor":"Wills Eye","startDate":"2017-07-10","conditions":"Glaucoma; Drugs, Normal Tension Glaucoma, Primary Open-angle Glaucoma","enrollment":35},{"nctId":"NCT04647461","phase":"PHASE4","title":"Comparison of Efficacy and Ocular Surface Disease Assessment Between BRIDIN-T Eye Drops 0.15% and ALPHAGAN-P Eye Drops 0.15% in Glaucoma or Ocular Hypertensive Patients : Phase 4, Parallel Group Design, Investigator-blind, Active-control, Randomized, Multi-center Trial","status":"UNKNOWN","sponsor":"CHA University","startDate":"2019-03-20","conditions":"Glaucoma, Ocular Hypertensive","enrollment":61},{"nctId":"NCT04633954","phase":"NA","title":"Brimonidine for Subconjunctival Hemorrhage From Femtosecond Laser Assisted Cataract Surgery","status":"COMPLETED","sponsor":"Uptown Eye Specialists","startDate":"2019-06-06","conditions":"Subconjunctival Hemorrhage, Cataract Surgery","enrollment":56},{"nctId":"NCT03966365","phase":"PHASE1","title":"Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-122 Compared With Krytantek Ofteno®","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2019-05-02","conditions":"Glaucoma","enrollment":24},{"nctId":"NCT03257813","phase":"PHASE3","title":"Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK)","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2016-04-01","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":60},{"nctId":"NCT02975557","phase":"PHASE1, PHASE2","title":"Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)","status":"TERMINATED","sponsor":"Sandeep Jain, MD","startDate":"2016-05","conditions":"Dry Eye, Ocular Graft vs Host Disease, Meibomian Gland Dysfunction","enrollment":15},{"nctId":"NCT01959243","phase":"PHASE3","title":"Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2014-02-22","conditions":"Hyperemia","enrollment":507},{"nctId":"NCT01959230","phase":"PHASE3","title":"Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2013-11-07","conditions":"Hyperemia","enrollment":60},{"nctId":"NCT03192826","phase":"PHASE4","title":"Brinzolamide/Brimonidine Combination vs Brimonidine 0.2% in the Prevention of IOP Rise After Nd-YAG Laser Capsulotomy","status":"COMPLETED","sponsor":"University Hospital of Patras","startDate":"2016-06-20","conditions":"Posterior Capsule Opacification, Ocular Hypertension","enrollment":79},{"nctId":"NCT03966560","phase":"PHASE4","title":"Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"Afyon Kocatepe University Hospital","startDate":"2014-01","conditions":"Glaucoma, Open-Angle","enrollment":96},{"nctId":"NCT02730871","phase":"PHASE4","title":"Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2016-06-24","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":173},{"nctId":"NCT01170884","phase":"PHASE4","title":"Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-12","conditions":"Glaucoma, Ocular Hypertension","enrollment":121},{"nctId":"NCT00811850","phase":"PHASE4","title":"Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow","status":"COMPLETED","sponsor":"Allergan","startDate":"2008-12","conditions":"Glaucoma","enrollment":15},{"nctId":"NCT03150160","phase":"PHASE4","title":"Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-09-21","conditions":"Glaucoma","enrollment":1},{"nctId":"NCT02419508","phase":"PHASE4","title":"SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2015-08-07","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":290},{"nctId":"NCT02818816","phase":"PHASE4","title":"Preoperative Brimonidine on IOP of Patients Undergoing RALP","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2016-02-29","conditions":"Prostate Cancer","enrollment":26},{"nctId":"NCT02863705","phase":"PHASE4","title":"Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG)","status":"COMPLETED","sponsor":"Allergan","startDate":"2016-07-05","conditions":"Glaucoma, Open-Angle, Normal Tension Glaucoma","enrollment":118},{"nctId":"NCT02339584","phase":"PHASE3","title":"Efficacy and Safety of Brinzolamide/Brimonidine Fixed Combination BID Compared to Brinzolamide BID Plus Brimonidine BID in Subjects With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2015-04-14","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":493},{"nctId":"NCT02967614","phase":"PHASE1","title":"KJ-TFC-004 Drug-drug Interaction Study","status":"COMPLETED","sponsor":"Kukje Pharma","startDate":"2016-12","conditions":"Glaucoma, Eye Diseases, Ocular Hypertension","enrollment":32},{"nctId":"NCT01535768","phase":"PHASE4","title":"Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves","status":"UNKNOWN","sponsor":"Credit Valley EyeCare","startDate":"2012-02","conditions":"Glaucoma","enrollment":150},{"nctId":"NCT02039765","phase":"PHASE1","title":"Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%.","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2014-02","conditions":"Hyperemia","enrollment":12},{"nctId":"NCT02718547","phase":"NA","title":"The Relationship Between Intraocular Pressure and Macular Edema in Patients With Diabetic Macular Edema","status":"UNKNOWN","sponsor":"Meir Medical Center","startDate":"2017-03-26","conditions":"Complications of Diabetes Mellitus","enrollment":25},{"nctId":"NCT01217606","phase":"PHASE3","title":"Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-01","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":185},{"nctId":"NCT00593359","phase":"","title":"Intraocular Pressure During Spine Surgery","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2007-12","conditions":"Intraocular Pressure","enrollment":60},{"nctId":"NCT01726075","phase":"PHASE2, PHASE3","title":"Trial to Assess the Efficacy of Neuroprotective Drugs Administered Topically to Prevent or Arrest Diabetic Retinopathy","status":"COMPLETED","sponsor":"BCN Peptides","startDate":"2013-02","conditions":"Diabetic Retinopathy","enrollment":450},{"nctId":"NCT02214680","phase":"PHASE2","title":"The Effect of Topical Treatment With Combigan Compared to Timolol and Brimonidine on Pupil Diameter","status":"UNKNOWN","sponsor":"Carmel Medical Center","startDate":"2015-10","conditions":"Healthy","enrollment":25},{"nctId":"NCT01937299","phase":"PHASE4","title":"Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-10","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":307},{"nctId":"NCT01863953","phase":"PHASE2","title":"A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-06","conditions":"Glaucoma, Ocular Hypertension","enrollment":112},{"nctId":"NCT01241240","phase":"PHASE3","title":"Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-03","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":192},{"nctId":"NCT01675609","phase":"PHASE2","title":"Study Evaluating the Safety and Efficacy of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Subjects","status":"COMPLETED","sponsor":"Eye Therapies, LLC","startDate":"2012-08","conditions":"Ocular Redness","enrollment":57},{"nctId":"NCT02140450","phase":"NA","title":"Effect of Antiglaucoma Agents on Short Term Intraocular Pressure Fluctuations After Intravitreal Bevacizumab Injection","status":"COMPLETED","sponsor":"Mashhad University of Medical Sciences","startDate":"2012-02","conditions":"Intraocular Pressure Change in Intravitreal Injection","enrollment":70},{"nctId":"NCT01309204","phase":"PHASE3","title":"Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-05","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":1184},{"nctId":"NCT01987752","phase":"","title":"Safety and Efficacy of Combigan® Ophthalmic Solution in Korea","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-01","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":732},{"nctId":"NCT01310777","phase":"PHASE3","title":"Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-05","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":771},{"nctId":"NCT01201551","phase":"NA","title":"Effect of Alphagan and Xalatan Eye Drops on Corneal Temperature","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2011-06","conditions":"Primary Vascular Dysregulation","enrollment":40},{"nctId":"NCT01525173","phase":"PHASE4","title":"A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":137},{"nctId":"NCT01216943","phase":"PHASE3","title":"Safety and Efficacy of Triple Combination Therapy in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-11","conditions":"Glaucoma, Ocular Hypertension","enrollment":126},{"nctId":"NCT01284166","phase":"PHASE3","title":"Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","status":"WITHDRAWN","sponsor":"Allergan","startDate":"2013-07","conditions":"Glaucoma, Ocular Hypertension","enrollment":""},{"nctId":"NCT01426867","phase":"PHASE2","title":"A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-09","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":103},{"nctId":"NCT01297920","phase":"PHASE3","title":"Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-03","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":1062},{"nctId":"NCT00961649","phase":"PHASE2","title":"Safety and Efficacy of Brinzolamide/Brimonidine Fixed Combination","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2009-10","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":195},{"nctId":"NCT01887223","phase":"PHASE2","title":"Transconjunctival Needling Revision Versus Medical Treatment","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2010-05","conditions":"Primary Open Angle Glaucoma","enrollment":40},{"nctId":"NCT01297517","phase":"PHASE3","title":"Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-02","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":1001},{"nctId":"NCT00800540","phase":"PHASE4","title":"Circadian Ocular Perfusion Pressure and Ocular Blood Flow","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2009-02","conditions":"Glaucoma","enrollment":35},{"nctId":"NCT01151904","phase":"PHASE4","title":"Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma Patients","status":"TERMINATED","sponsor":"Allergan","startDate":"2009-11","conditions":"Glaucoma, Angle-Closure","enrollment":17},{"nctId":"NCT01687426","phase":"PHASE1","title":"Study Evaluating the Safety and Intraocular Pressure (IOP) Lowering Response of Brimonidine Tartrate Ophthalmic Solution in Subjects With Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Eye Therapies, LLC","startDate":"2012-09","conditions":"Glaucoma and Ocular Hypertension","enrollment":15},{"nctId":"NCT01229462","phase":"NA","title":"Safety and Efficacy of Brimonidine Tartrate/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-10","conditions":"Glaucoma, Ocular Hypertension","enrollment":238},{"nctId":"NCT01255306","phase":"","title":"The Influence of Silicone Oil on Nerve Fiber Layer Thickness After Pars Plana Vitrectomy","status":"COMPLETED","sponsor":"University Hospital Sestre Milosrdnice","startDate":"2010-04","conditions":"Rhegmatogenous Retinal Detachment, Toxic Effect of Silicone, Glaucoma Due to Silicon Oil","enrollment":60},{"nctId":"NCT01275105","phase":"PHASE2","title":"A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)","status":"COMPLETED","sponsor":"Eye Therapies, LLC","startDate":"2011-01","conditions":"Allergic Conjunctivitis","enrollment":68},{"nctId":"NCT01446497","phase":"PHASE4","title":"Efficacy and Safety Study of Combigan and 0.5% Timoptic in Normal Tension Glaucoma","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2010-10","conditions":"Normal Tension Glaucoma","enrollment":22},{"nctId":"NCT00811564","phase":"PHASE4","title":"An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects","status":"COMPLETED","sponsor":"Allergan","startDate":"2008-12","conditions":"Glaucoma, Ocular Hypertension","enrollment":148},{"nctId":"NCT01250236","phase":"","title":"Effect of Brimonidine on Corneal Thickness","status":"UNKNOWN","sponsor":"Augenarztpraxis Breisach","startDate":"2010-12","conditions":"Impact of Brimonidine on the Cornea","enrollment":10},{"nctId":"NCT01004900","phase":"PHASE3","title":"Intraocular Pressure (IOP) Lowering Effect of Selective Laser Trabeculoplasty Versus Prostaglandin Analogues in Angle Closure Glaucoma","status":"UNKNOWN","sponsor":"Singapore Eye Research Institute","startDate":"2009-06","conditions":"Glaucoma","enrollment":90},{"nctId":"NCT00061529","phase":"PHASE3","title":"A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2003-01","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Alphagan®","Concomitant triple therapy"],"phase":"marketed","status":"active","brandName":"brimonidine tartrate ophthalmic solution","genericName":"brimonidine tartrate ophthalmic solution","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Brimonidine tartrate is an alpha-2 adrenergic receptor agonist that reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}